X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5974) 5974
Book Review (1390) 1390
Publication (723) 723
Conference Proceeding (42) 42
Newsletter (35) 35
Book Chapter (16) 16
Newspaper Article (9) 9
Magazine Article (6) 6
Paper (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bortezomib (5216) 5216
index medicus (5034) 5034
humans (4901) 4901
oncology (2385) 2385
multiple myeloma - drug therapy (2137) 2137
male (2128) 2128
multiple myeloma (2126) 2126
female (2047) 2047
hematology (2014) 2014
middle aged (1766) 1766
aged (1597) 1597
antineoplastic agents - therapeutic use (1538) 1538
boronic acids - therapeutic use (1530) 1530
pyrazines - therapeutic use (1517) 1517
antineoplastic combined chemotherapy protocols - therapeutic use (1514) 1514
treatment outcome (1291) 1291
cancer (1188) 1188
adult (1142) 1142
animals (1003) 1003
apoptosis (964) 964
boronic acids - administration & dosage (935) 935
pyrazines - administration & dosage (934) 934
dexamethasone (892) 892
chemotherapy (861) 861
therapy (851) 851
proteasome inhibitors (813) 813
care and treatment (767) 767
multiple-myeloma (704) 704
stem-cell transplantation (703) 703
boronic acids - pharmacology (699) 699
cell line, tumor (697) 697
lenalidomide (696) 696
thalidomide (695) 695
pyrazines - pharmacology (689) 689
antineoplastic agents - pharmacology (686) 686
thalidomide - analogs & derivatives (677) 677
aged, 80 and over (662) 662
multiple myeloma - pathology (657) 657
survival (637) 637
dexamethasone - administration & dosage (619) 619
transplantation (613) 613
apoptosis - drug effects (587) 587
mice (551) 551
drug therapy (548) 548
prognosis (548) 548
research (541) 541
multiple myeloma - therapy (519) 519
thalidomide - therapeutic use (511) 511
thalidomide - administration & dosage (510) 510
multiple myeloma - mortality (501) 501
boronic acids - adverse effects (496) 496
pyrazines - adverse effects (494) 494
antineoplastic combined chemotherapy protocols - adverse effects (480) 480
recurrence (478) 478
analysis (476) 476
proteasome inhibitor bortezomib (474) 474
pharmacology & pharmacy (469) 469
article (466) 466
protease inhibitors - therapeutic use (459) 459
health aspects (435) 435
medicine & public health (430) 430
proteins (421) 421
nf-kappa-b (418) 418
bortezomib - therapeutic use (417) 417
hematology, oncology and palliative medicine (414) 414
antineoplastic agents - adverse effects (391) 391
combination (391) 391
proteasome endopeptidase complex - metabolism (377) 377
disease-free survival (376) 376
retrospective studies (372) 372
abridged index medicus (368) 368
stem cells (364) 364
trial (361) 361
expression (352) 352
proteasome inhibitor (352) 352
multiple myeloma - diagnosis (351) 351
dosage and administration (350) 350
hemic and lymphatic diseases (348) 348
antineoplastic agents - administration & dosage (344) 344
drug resistance, neoplasm (335) 335
survival analysis (333) 333
proteasome (332) 332
myeloma (330) 330
patients (330) 330
transplantation, autologous (330) 330
clinical trials as topic (326) 326
multiple myeloma - complications (324) 324
stem cell transplantation (323) 323
dexamethasone - therapeutic use (319) 319
dose-response relationship, drug (312) 312
bortezomib - administration & dosage (309) 309
cells (308) 308
multiple myeloma - genetics (307) 307
rituximab (307) 307
cell biology (305) 305
melphalan (296) 296
proteasome inhibitors - pharmacology (287) 287
clinical trials (285) 285
proteasome inhibitors - therapeutic use (285) 285
lymphomas (282) 282
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5740) 5740
Japanese (87) 87
Chinese (76) 76
French (39) 39
Czech (19) 19
German (19) 19
Spanish (15) 15
Russian (12) 12
Polish (10) 10
Hungarian (8) 8
Italian (3) 3
Danish (2) 2
Croatian (1) 1
Dutch (1) 1
Korean (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Cell, ISSN 1535-6108, 09/2012, Volume 22, Issue 3, pp. 345 - 358
Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting... 
DEUBIQUITINATING ENZYME | INACTIVATION | PROTEIN | THERAPY | ONCOLOGY | MDM2 | DEGRADATION | MECHANISMS | HAUSP | CANCER | P53 REGULATION | CELL BIOLOGY | Thiophenes - therapeutic use | Apoptosis - drug effects | Humans | Molecular Sequence Data | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Thalidomide - pharmacology | Boronic Acids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Protease Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Dexamethasone - pharmacology | Antineoplastic Agents - pharmacology | Drug Therapy, Combination | Multiple Myeloma - enzymology | Protease Inhibitors - therapeutic use | Proto-Oncogene Proteins c-mdm2 - metabolism | Ubiquitin Thiolesterase - antagonists & inhibitors | Bortezomib | Cyclin-Dependent Kinase Inhibitor p21 - antagonists & inhibitors | Thiophenes - pharmacology | Random Allocation | Mice, SCID | Ubiquitin Thiolesterase - genetics | Xenograft Model Antitumor Assays | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Mice | Thalidomide - therapeutic use | Pyrazines - pharmacology | Ubiquitin-Specific Peptidase 7 | Boronic Acids - pharmacology | Drug Resistance, Neoplasm - drug effects | Medical colleges | Dexamethasone | Proteases | Analysis | Multiple myeloma | Lymphomas | Apoptosis | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10068, pp. 519 - 527
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2015, Volume 90, Issue 11, pp. 981 - 985
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2015, Volume 372, Issue 10, pp. 944 - 953
Journal Article
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | SURVIVAL | PLUS DEXAMETHASONE | COMPLETE REMISSION | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2012, Volume 30, Issue 24, pp. 2946 - 2955
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1617 - 1629
Summary Background High-dose melphalan plus autologous stem-cell transplantation (ASCT) is the standard approach in transplant-eligible patients with newly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | ONCOLOGY | CONSOLIDATION THERAPY | INITIAL TREATMENT | THALIDOMIDE | BORTEZOMIB | INDUCTION | STEM-CELL TRANSPLANTATION | DEXAMETHASONE COMBINATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Melphalan - therapeutic use | Hematopoietic Stem Cell Transplantation - mortality | Cyclophosphamide - therapeutic use | Thalidomide - analogs & derivatives | Multiple Myeloma - therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Maintenance Chemotherapy | Chemotherapy, Adjuvant | Thalidomide - adverse effects | Prednisone - adverse effects | Multiple Myeloma - diagnosis | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Disease-Free Survival | Czech Republic | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Thalidomide - therapeutic use | Australia | Prednisone - therapeutic use | Medical colleges | Cyclophosphamide | Care and treatment | Chemotherapy | Dexamethasone | Multiple myeloma | Stem cells | Product development | Prednisone | Transplantation | Cancer | Index Medicus
Journal Article
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, ISSN 1520-4391, 12/2015, Volume 2015, Issue 1, pp. 529 - 544
Journal Article